Michael V Kerrigan

Array ( [id] => 2970844 [patent_doc_number] => 05258499 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1993-11-02 [patent_title] => 'Liposome targeting using receptor specific ligands' [patent_app_type] => 1 [patent_app_number] => 7/850019 [patent_app_country] => US [patent_app_date] => 1992-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 7925 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/258/05258499.pdf [firstpage_image] =>[orig_patent_app_number] => 850019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2888452 [patent_doc_number] => 05238922 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1993-08-24 [patent_title] => 'Inhibitors of farnesyl protein transferase' [patent_app_type] => 1 [patent_app_number] => 7/770078 [patent_app_country] => US [patent_app_date] => 1991-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7022 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/238/05238922.pdf [firstpage_image] =>[orig_patent_app_number] => 770078 [rel_patent_id] =>[rel_patent_doc_number] =>)